News
Dive into the latest news, press releases and reports from the Abacus Medicine Group.
Abacus Medicine Group: Record full-year result
The Abacus Medicine Group exceeded the guidance ranges for both revenue and profitability in 2023. A combination of high demand in core sales markets and solid commercial execution drove organic revenue growth of 18% to EUR 1,210 million and EBITDA growth of 82% to EUR 47.5 million.
The main shareholders in Abacus Medicine A/S nominate Jens Harsaae as new Chairman of the Board
Jens Harsaae is being nominated as new Chairman of Abacus Medicine A/S by the main shareholders.
Sune Vorre appointed new Chief Information Officer (CIO) of the Abacus Medicine Group
The Abacus Medicine Group has appointed Sune Vorre as its new Group CIO, and member of the chief executive management team.
Abacus Medicine Group upgrades full-year outlook
Based on strong performance and growing demand in core markets the Abacus Medicine Group is upgrading the full-year outlook for 2023.
Abacus Medicine Pharma Services and Laboratoires CTRS extend partnership to improve access to Orphacol® in Spain
Abacus Medicine Pharma Services (AMPS) and Laboratoires CTRS, marketing authorization holder of Orphacol®, are proud to announce a strategic partnership that ensures continuous stock of Orphacol® in Spain.
Sustainability Report 2022: The Abacus Medicine Group continued to work with sustainability and ESG within 6 focus programs
A materiality assessment, an official Diversity & Inclusion strategy, and workshops for increased awareness of sustainability and ESG across the company were among the concrete initiatives in the Group’s strategic sustainability efforts.
